1. http://www.mz.gov.pl/

2. Główny Urząd Statystyczny, Roczniki statystyczne, Rocznik Demograficzny 2015, Warszawa, ss. 346-347.

3. Kośmicki M. Choroba wieńcowa w praktyce lekarza ogólnego. Podstawowe zasady postępowania diagnostyczno-terapeutycznego. Poznań: Termedia, 2010, s.1

4. Montalescot G, Sechtem U, Achenbach S, et al. 2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology. Eur Heart J. 2013; 34: 2949-3003.

5. Perk J, De Backer G, Gohlke H, et al. European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). Eur Heart J. 2012; 33: 1635-1701.

6. Critchley J, Capewell S. Smoking cessation for the secondary prevention of coronary heart disease. Cochrane Database Syst Rev 2004 (1): CD003041.

7. Heatherton TF, Kozlowski LT, Frecker RC, Fagerström KO. The Fagerström Test for Nicotine Dependence: a revision of the Fagerström Tolerance Questionnaire. Br J Addict. 1991; 86: 1119-1127.

8. O’Keefe JH, Bhatti SK, Bajwa A. Alcohol and cardiovascular health: the dose makes the poison…or the remedy. Mayo Clin Proc. 2014; 89: 382-393.

9. http://www.zus.pl/

10. Ciszewski A, Bilinska ZT, Brydak LB, et al. Influenza vaccination in secondary prevention from coronary ischaemic events in coronary artery disease: FLUCAD study. Eur Heart J 2008; 29: 1350–1358.

11. Cannon CP, Blazing MA, Giugliano RP. Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes. N Engl J Med. 2015; 372: 2387-2397.

12. Dagenais GR, Pogue J, Fox K, Simoons ML, Yusuf S. Angiotensin- converting-enzyme inhibitors in stable vascular disease without left ventricular systolic dysfunction or heart failure: a combined analysis of three trials. Lancet 2006;368:581–588.

13. Mann JF, Schmieder RE, McQueen M, et al. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (theONTARGET study): a multicentre, randomised, doubleblind, controlled trial. Lancet 2008; 372: 547–553.

14. Ozasa N, Morimoto T, Bao B, et al. beta-blocker use in patients after percutaneous coronary interventions: one size fits all? Worse outcomes in patients without myocardial infarction or heart failure. Int J Cardiol 2013;168:774-779.

15. Fox K, Ford I, Steg PG, et al. Ivabradine in stable coronary artery disease without clinical heart failure. N Engl J Med. 2014; 371: 1091-1099.

16. Timmis AD, Chaitman BR, Crager M. Effects of ranolazine on exercise tolerance and HbA1c in patients with chronic angina and diabetes. Eur. Heart J. 2006; 27: 42–48.

17. Morrow DA, Scirica BM, Karwatowska-Prokopczuk E, et al. Effects of ranolazine on recurrent cardiovascular events in patients with non-ST-elevation acute coronary syndromes: the MERLINTIMI 36 randomized trial. JAMA. 2007; 297: 1775–1783.

18. Cattaneo M, Porretta AP, Gallino A. Ranolazine: Drug overview and possible role in primary microvascular angina management. Int J Cardiol. 2015; 181: 376-81.

19. Daly CA, De Stavola B, Sendon JL, et al. Predicting prognosis in stable angina: results from the Euro heart survey of stable angina: prospective observational study. BMJ 2006; 332:262–267.

20. Tykarski A, Narkiewicz K, Gaciong Z. Zasady postępowania w nadciśnieniu tętniczym – 2015 rok. Nadciśnienie tętnicze w Praktyce. 2015; 1: 1-70.

21. Gerstein HC, Miller ME, Ismail-B